Brooks Laboratories (BROOKS) Q2 FY27 Profit Jumps 747% on a One-Time Stake Sale
A ₹74.7 crore exceptional gain from divesting a stake delivered a massive profit, but revenue fell 18% as the core business struggled.
Brooks Laboratories posted a consolidated net profit of ₹67.61 crore for Q2 FY27, a 747% jump year-on-year. This surge was driven by a one-time stake sale, while operating revenue declined sharply, highlighting underlying business pressure.
For Brooks Laboratories, the September quarter was a story of two sharply different realities. While a headline profit of ₹67.61 crore shows a massive turnaround, the underlying pharmaceutical business faced a deepening slowdown.
The numbers reveal the split. Revenue from operations fell 18% year-on-year to ₹19.25 crore, continuing a sequential decline. Yet, net profit soared 747% from the same quarter last year, swinging from a loss in the prior quarter.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Period | Sep 2026 | Jun 2026 | Sep 2025 |
| Revenue (₹ Cr) | 19.25YoY -18% | 22.96 | 23.45 |
| Profit (₹ Cr) | 67.61YoY +747% | -1.79 | 7.98 |
The One-Off That Explains Everything
The profit surge was almost entirely due to a non-recurring event. According to a report by ScanX.trade, the company booked an exceptional gain of ₹74.70 crore from the partial divestment of its stake in Brooks Steriscience Limited. This single item accounted for over 90% of the pre-tax profit.
Stripping out this gain reveals a much weaker operational picture. ScanX.trade notes the consolidated business recorded a loss of ₹1.77 crore before the exceptional item. The manufacturing segment's profit fell by more than half compared to the year-ago quarter.
Why the Core Business is Struggling
The revenue decline came despite a generally supportive market. The domestic pharmaceutical market grew 12% in value during the quarter, according to a Moneycontrol report citing Pharmarack data. Brooks Labs appears to have missed this broad recovery.
Costs provided little relief. While material costs fell with lower sales, employee expenses rose 6% year-on-year. This created pressure on margins as fixed costs were spread over a shrinking revenue base.
A Balance Sheet Boost With a Catch
The stake sale significantly strengthened the company's financial position. ScanX.trade reports that total equity increased substantially, and a large portion of the sale proceeds moved into bank balances. However, operating cash flow for the half-year remained negative at ₹3.34 crore, indicating working capital strain.
Looking ahead, the company's strategic focus is on a planned demerger. An analysis by StockFin.ai notes the board is pursuing regulatory clearances to separate its manufacturing business into a new listed entity, Abridge Speciality Limited.
Key Points
- The ₹67.61 crore net profit was driven by a one-time ₹74.70 crore gain from divesting a stake in Brooks Steriscience Limited.
- Core operations weakened as revenue fell 18% year-on-year to ₹19.25 crore, with the manufacturing segment's profit declining sharply.
- The stake sale boosted the balance sheet but operating cash flow remained negative, pointing to underlying working capital pressure.
- The company's strategic path involves a planned demerger of its manufacturing business, as it seeks regulatory approvals.
Hexa Perspective
The quarter presents a clear divergence between a fortified balance sheet and a struggling operating engine. The liquidity from the asset sale provides a buffer, but it does not solve the fundamental challenge of declining sales in a growing market.
Investors are left weighing a one-time cash infusion against the sustainability of the core injectables business. The planned demerger could bring strategic focus, but its success hinges on reversing the operational slide first. The stock's deep discount to the industry, trading at a P/E of 4.5, reflects this uncertainty.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
